Hashemi Mohammad, Moazeni-Roodi Abdolkarim, Taheri Mohsen
Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.
Department of Clinical Biochemistry, School of Medicine, Iranshahr University of Medical Sciences, Iranshahr, Iran.
Asia Pac J Clin Oncol. 2019 Dec;15(6):275-287. doi: 10.1111/ajco.13107. Epub 2019 Jan 29.
Previous studies have found inconsistent results regarding gene deletion in APOBEC3 (apolipoprotein B mRNA-editing catalytic polypeptide-like 3) and risk of cancer. We conducted a meta-analysis of all eligible case-control studies to find out the associations between APOBEC3 deletion and cancer risk by pooling the odds ratios (ORs) and corresponding 95% confidence intervals (CIs). Overall, the findings from 20 studies (13 articles) involving of a total of 26 225 cases and 37 201 controls revealed that DD genotype was associated significantly with increased cancer risk compared to II genotype (OR = 1.25, 95% CI = 1.01-1.56, P = 0.04). Stratified analysis from 10 studies including 14 757 cases and 17 930 controls revealed that I/D variant significantly increased the risk of breast cancer in heterozygous codominant (OR = 1.15, 95% CI = 1.03-1.28, P = 0.02, ID vs II), dominant (OR = 1.15, 95% CI = 1.01-1.31, P = 0.03, ID + DD vs II), overdominant (OR = 1.11, 95% CI = 1.05-1.25, P < 0.0001, ID vs DD + II) and allele (OR = 1.15, 95% CI = 1.13-1.25, P = 0.03, D vs I) inheritance models. In conclusion, the data propose that APOBEC3 deletion is significantly associated with increased susceptibility to cancer in overall and breast cancer. Our findings require well-designed replication in a larger independent genetic association study with larger sample sizes in diverse ethnicities.
以往的研究在载脂蛋白B mRNA编辑催化多肽样3（APOBEC3）基因缺失与癌症风险方面得到了不一致的结果。我们对所有符合条件的病例对照研究进行了一项荟萃分析，通过汇总比值比（OR）和相应的95%置信区间（CI）来找出APOBEC3缺失与癌症风险之间的关联。总体而言，来自20项研究（13篇文章）、共涉及26225例病例和37201例对照的研究结果显示，与II基因型相比，DD基因型与癌症风险增加显著相关（OR = 1.25，95% CI = 1.01 - 1.56，P = 0.04）。来自10项研究（包括14757例病例和17930例对照）的分层分析显示，在杂合共显性（OR = 1.15，95% CI = 1.03 - 1.28，P = 0.02，ID vs II）、显性（OR = 1.15，95% CI = 1.01 - 1.31，P = 0.03，ID + DD vs II）、超显性（OR = 1.11，95% CI = 1.05 - 1.25，P < 0.0001，ID vs DD + II）和等位基因（OR = 1.15，95% CI = 1.13 - 1.25，P = 0.03，D vs I）遗传模型中，I/D变异显著增加了患乳腺癌的风险。总之，数据表明APOBEC3缺失与总体癌症易感性增加以及乳腺癌显著相关。我们的研究结果需要在更大规模、不同种族、样本量更大的独立基因关联研究中进行精心设计的重复验证。
